Algert Global LLC purchased a new stake in Arbutus Biopharma Corp (NASDAQ:ABUS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 34,816 shares of the biopharmaceutical company’s stock, valued at approximately $254,000. Algert Global LLC owned 0.06% of Arbutus Biopharma as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. DekaBank Deutsche Girozentrale purchased a new position in Arbutus Biopharma in the 1st quarter worth approximately $174,000. Two Sigma Investments LP bought a new stake in shares of Arbutus Biopharma in the 4th quarter worth approximately $215,000. Goldman Sachs Group Inc. bought a new stake in shares of Arbutus Biopharma in the 4th quarter worth approximately $275,000. Citadel Advisors LLC lifted its holdings in shares of Arbutus Biopharma by 124.9% in the 1st quarter. Citadel Advisors LLC now owns 64,797 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 35,981 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Arbutus Biopharma by 309.1% during the 4th quarter. Millennium Management LLC now owns 82,007 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 61,961 shares during the last quarter. 40.05% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ABUS traded up $0.10 during midday trading on Friday, reaching $9.10. The company’s stock had a trading volume of 177,000 shares, compared to its average volume of 292,405. The company has a market capitalization of $506.95 million, a PE ratio of -5.07 and a beta of 1.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.67 and a quick ratio of 13.67. Arbutus Biopharma Corp has a 12-month low of $4.10 and a 12-month high of $12.60.
ABUS has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Arbutus Biopharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 23rd. Zacks Investment Research lowered shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Chardan Capital reiterated a “buy” rating and set a $11.00 price target on shares of Arbutus Biopharma in a report on Monday, July 16th. B. Riley upped their price objective on shares of Arbutus Biopharma from $9.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, August 13th. Finally, Wedbush upped their price objective on shares of Arbutus Biopharma from $6.00 to $7.00 and gave the stock a “hold” rating in a report on Monday, August 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company’s stock. Arbutus Biopharma presently has an average rating of “Buy” and a consensus price target of $9.58.
In related news, insider Michael J. Sofia sold 20,000 shares of the stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $8.20, for a total transaction of $164,000.00. Following the sale, the insider now directly owns 1,543,403 shares of the company’s stock, valued at approximately $12,655,904.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael J. Sofia sold 4,250 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $9.51, for a total transaction of $40,417.50. Following the sale, the insider now directly owns 1,499,153 shares in the company, valued at $14,256,945.03. The disclosure for this sale can be found here. Insiders sold a total of 54,250 shares of company stock worth $473,518 over the last ninety days. Insiders own 7.60% of the company’s stock.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Further Reading: Trading Strategy
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.